BioCardia, Inc. (NASDAQ:BCDA – Get Rating) saw a large decrease in short interest in the month of May. As of May 15th, there was short interest totalling 388,200 shares, a decrease of 38.1% from the April 30th total of 627,000 shares. Based on an average trading volume of 703,800 shares, the days-to-cover ratio is presently 0.6 days. Currently, 3.0% of the company’s shares are short sold.
Several equities research analysts recently weighed in on the company. Maxim Group dropped their target price on BioCardia to $4.00 in a report on Thursday. Brookline Capital Management reiterated a “buy” rating on shares of BioCardia in a report on Thursday, February 3rd. Finally, Zacks Investment Research upgraded BioCardia from a “sell” rating to a “hold” rating in a report on Monday, April 11th.
NASDAQ BCDA opened at $1.66 on Friday. BioCardia has a fifty-two week low of $1.10 and a fifty-two week high of $5.10. The stock has a 50 day simple moving average of $1.72 and a two-hundred day simple moving average of $1.92. The stock has a market cap of $28.96 million, a P/E ratio of -2.18 and a beta of 1.40.
Several large investors have recently made changes to their positions in BCDA. Renaissance Technologies LLC bought a new position in shares of BioCardia in the 1st quarter worth approximately $28,000. Millennium Management LLC bought a new position in shares of BioCardia in the 3rd quarter worth approximately $31,000. Dimensional Fund Advisors LP bought a new position in shares of BioCardia in the 1st quarter worth approximately $57,000. Commonwealth Equity Services LLC raised its position in shares of BioCardia by 156.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 42,307 shares of the company’s stock worth $82,000 after acquiring an additional 25,815 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in shares of BioCardia in the 4th quarter worth approximately $109,000. 15.40% of the stock is owned by hedge funds and other institutional investors.
About BioCardia (Get Rating)
BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease.
- Get a free copy of the StockNews.com research report on BioCardia (BCDA)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.